Autopsy report · NCT01011439
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
Cause of deathRegulatory or ethics
“For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved at INT Milano.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 8 years 10 months before it stopped.
- 72 participants enrolled.
- Results were posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Tiziana Life Sciences LTD
- Sponsor type
- Industry
- Conditions
- Thymic Carcinoma
- Interventions
- Milciclib Maleate
- Participants
- 72
- Sites
- 6
- Countries
- France, Italy, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.